Navigation Links
eFFECTOR Therapeutics' Lead Product Candidate, eFT508, Receives Orphan Designation from FDA for Treatment of Diffuse Large B-Cell Lymphoma
Date:3/9/2017

SAN DIEGO, March 9, 2017 /PRNewswire/ -- eFFECTOR Therapeutics today announced that its lead product candidate, eFT508, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin lymphoma. eFT508 is a potent, highly selective inhibitor of MNK1 and MNK2, two enzymes that are critical for the growth and survival of tumors. eFFECTOR also announced that it has dosed the first subject in a Phase 1/2 clinical trial of eFT508 in patients with B-cell hematological malignancies.

"Diffuse large B-cell lymphoma is an aggressive disease for which patients badly need additional treatment options," said Steve Worland, Ph.D., president and chief executive officer of eFFECTOR. "We hope that eFT508, a selective translation regulator that blocks multiple oncogenic growth and proliferation pathways, as well as activates anti-tumor immunity, will prove effective in treating patients afflicted with this devastating disease."

The recently initiated trial is a Phase 1/2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics and antitumor activity of eFT508. The primary goals will be to establish a maximum tolerated dose and recommended dose for further evaluation and to assess preliminary efficacy of the compound. eFFECTOR is also conducting a Phase 1/2 dose escalation trial of eFT508 in patients with solid tumors.

Orphan designation is granted by the FDA Office of Orphan Products Development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the United States. The orphan designation of eFT508 for DLBCL provides increased access to FDA reviewers to discuss clinical trial designs, the ability to qualify for tax credits for certain clinical research costs, the ability to apply for annual grant funding, and a waiver of Prescription Drug User Fee Act filing fees, as well as the potential for seven years of U.S. marketing exclusivity if the product candidate is approved.

About eFT508
eFT508 is a potent, highly selective and orally bioavailable inhibitor of MNK1 and MNK2 being studied in patients with solid tumors and lymphoma. MNK1 and 2 are kinases acting as signal integrators at the convergence of multiple oncogenic pathways to regulate production of disease-driving proteins, including checkpoint proteins.

About Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma is an aggressive form of non-Hodgkin lymphoma (NHL) that can begin in lymph nodes and areas of the body outside of the lymphatic system. DLBCL is the most common form of NHL, making up 30 percent of newly-diagnosed NHL cases each year, according to the Lymphoma Research Foundation. Due to the fast-acting and aggressive nature of the disease, DLBCL requires immediate treatment upon diagnosis.

About eFFECTOR Therapeutics
eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of selective translation regulators as a new class of small molecule therapeutics for cancer. The company's investigational compounds are designed to restore translational control to halt underlying disease mechanisms while preserving healthy physiological processes. eFFECTOR's most advanced program focuses on the development of eFT508. The company has additional selective translation regulator programs currently in discovery and development. For more information visit www.effector.com.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/effector-therapeutics-lead-product-candidate-eft508-receives-orphan-designation-from-fda-for-treatment-of-diffuse-large-b-cell-lymphoma-300420884.html


'/>"/>
SOURCE eFFECTOR Therapeutics
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. eFFECTOR Therapeutics Appoints Alana McNulty Chief Financial Officer
2. Peer-Reviewed Study in Cell Validates eFFECTOR Therapeutics Novel Small-Molecule Approach to Cancer Treatment
3. First patent issues on TAL effector technology
4. Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
5. Orexigen Therapeutics to Provide Business Update and Discuss Fourth Quarter and Year End 2016 Financial Results on March 28, 2017
6. UNIAPAC Foundation Think Tank in Paris selects Renova Therapeutics CEO and Co-founder as keynote speaker for annual meeting
7. Envisia Therapeutics To Present At American Glaucoma Society 2017 Annual Meeting
8. Stealth BioTherapeutics Initiates Observational Study of Patients With Mitochondrial Myopathy
9. Sangamo Therapeutics Announces Presentation At The Cowen And Company 37th Annual Health Care Conference
10. Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results
11. Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... The Academy ... Colorado October 28 and 29, 2017, to promote AMA’s programs, member services, and ... in different hobbies, including but not limited to model aviation and other RC ...
(Date:9/21/2017)... ... September 21, 2017 , ... Dr. Greg Leyer, Chief Scientific ... on September 27th. His presentation is at 12:10pm in the Probiotics Resource Center, Mandalay ... at SupplySide West and discuss how probiotics have shown impressive data in areas outside ...
(Date:9/21/2017)... UK (PRWEB) , ... September 21, 2017 , ... ... a QuintilesIMS company, who enable the world’s most progressive pharma and biotech organizations ... clinical trials at top pharma and biotech events in Q4. , DrugDev will ...
(Date:9/21/2017)... ... September 21, 2017 , ... Lajollacooks4u welcomed the San ... The organization, a worldwide society of professional women with high achievement in the fields ... annual dinner. , Twelve members began with an olive oil tasting to ...
Breaking Biology Technology:
(Date:8/15/2017)...   ivWatch LLC , a medical device company focused on ... receipt of its ISO 13485 Certification, the global standard for medical ... Standardization (ISO®). ... Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as ...
(Date:5/23/2017)... 2017  Hunova, the first robotic gym for the rehabilitation and functional ... in Genoa, Italy . The first 30 robots will ... USA . The technology was developed and patented at ... IIT spin-off Movendo Technology thanks to a 10 million euro investment from ... click: ...
(Date:4/19/2017)... 19, 2017 The global military ... is marked by the presence of several large global ... by five major players - 3M Cogent, NEC Corporation, ... for nearly 61% of the global military biometric market ... the global military biometrics market boast global presence, which ...
Breaking Biology News(10 mins):